Trial Profile

A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer
Focus Adverse reactions
Sponsors Yakult Honsha

Most Recent Events

30 Oct 2018 Status changed from active, no longer recruiting to completed.
11 Jul 2018 Results assessing the tolerability of combined therapy with resminostat/ S-1 and determining the optimal regimen for subsequent investigations published in the Investigational New Drugs
13 Sep 2017 Results presented in a 4SC media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com